Wang, Yaolin
InventisBio Co., Ltd. (China)
3 papers on CoChatORCID 0000-0003-2662-3858
Most cited papers
- Verified
D‐1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity
Shi, Z., Weng, J., Niu, H., Yang, H., Liu, R., Weng, Y., Zhu, Q., Zhang, Y., Tao, L., Wang, Z., et al. (2023) · Cancer Science
Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways
Cited by 38
- Verified
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
Ruan, D.-Y., Wu, H.-X., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., Yan, D., Lee, M.-A., Lee, K.-W., Pan, H., et al. (2025) · Signal Transduction and Targeted Therapy
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 22
- Verified
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer
Yamamoto, N., Yan, D., Ganju, V., Hou, X., Pan, H., Shan, J., Wang, L., Kim, S.-W., Richardson, G., Sanborn, R. E., et al. (2026) · British Journal of Cancer
Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment
Cited by 5
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free